| XLS |
|
|
|
|
|
| ||
|
€ million |
Q3 2012 |
Q3 2011* |
Jan.–Sept. |
Jan.–Sept. | ||
| ||||||
|
Profit after tax |
188.7 |
227.2 |
303.3 |
481.9 | ||
|
Available-for-sale financial assets |
|
|
|
| ||
|
Fair value adjustments |
1.1 |
–3.2 |
1.2 |
26.1 | ||
|
Reclassification to income statement |
– |
0.2 |
– |
–27.0 | ||
|
Deferred taxes |
– |
0.8 |
– |
1.4 | ||
|
Changes recognized in equity |
1.1 |
–2.2 |
1.2 |
0.5 | ||
|
Derivative financial instruments |
|
|
|
| ||
|
Fair value adjustments |
7.9 |
–45.8 |
–43.1 |
–32.6 | ||
|
Reclassification to income statement |
10.7 |
–3.2 |
65.0 |
–6.8 | ||
|
Deferred taxes |
–3.0 |
7.8 |
–1.8 |
7.6 | ||
|
Changes recognized in equity |
15.6 |
–41.2 |
20.2 |
–31.8 | ||
|
Remeasurement of the net defined benefit liability |
|
|
|
| ||
|
Changes in remeasurement |
–97.1 |
–2.0 |
–106.9 |
– | ||
|
Deferred taxes |
16.6 |
0.8 |
14.7 |
0.9 | ||
|
Changes recognized in equity |
–80.5 |
–1.2 |
–92.2 |
0.9 | ||
|
Exchange differences on translating foreign operations |
|
|
|
| ||
|
Changes taken directly to equity |
–8.6 |
–32.7 |
33.4 |
–75.1 | ||
|
Reclassification to income statement |
– |
– |
– |
3.5 | ||
|
Changes recognized in equity |
–8.6 |
–32.7 |
33.4 |
–71.6 | ||
|
Gains/losses recognized immediately in equity |
–72.4 |
–77.3 |
–37.4 |
–102.0 | ||
|
Comprehensive income |
116.4 |
149.9 |
265.9 |
379.9 | ||
|
of which attributable to Merck KGaA shareholders |
112.5 |
146.2 |
258.0 |
374.4 | ||
|
of which attributable to non-controlling interest |
3.9 |
3.7 |
7.9 |
5.5 | ||